Journal ArticleDOI
Recurrence rates in patients with HER2+ breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant trastuzumab: a real-world evidence study.
Joyce O'Shaughnessy,Nicholas J. Robert,Srinivas Annavarapu,Jie Zhou,Jesse Sussell,Anna Cheng,Anita Fung +6 more
TLDR
In this paper, the authors assessed real-world risk of invasive disease recurrence (IDR) and associated factors in patients with human epidermal growth factor receptor-2 positive (HER2+) early breast cancer (BC) with pathological complete responses (pCR) after neoadjuvant pertuzumab plus trastuzumaab (nPT) plus chemotherapy, followed by adjuvant trastusumab (aT), patients with HER2+ BC with pCR after nPT from 2013 to 2015 who received aT were identified in the US OncAbstract:
This study assessed real-world risk of invasive disease recurrence (IDR) and associated factors in patients with human epidermal growth factor receptor-2 positive (HER2+) early breast cancer (BC) with pathological complete responses (pCR) after neoadjuvant pertuzumab plus trastuzumab (nPT) plus chemotherapy, followed by adjuvant trastuzumab (aT). Patients with HER2+ BC with pCR after nPT from 2013 to 2015 who received aT were identified in the US Oncology Network and followed until IDR or censoring. Kaplan–Meier and Cox regression methods were used to assess invasive disease-free survival (iDFS) and correlation between iDFS and patient characteristics. A total of 217 pCR patients’ charts were reviewed; median age was 52 years. Most had stage IIA or IIB disease (62%), Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 1 (84%), tumor size > 2 cm (75%), positive nodes (N+, 62%) and negative estrogen and progesterone receptor (ER− and PR−) expression (52%). Four-year iDFS rates were 90.0% overall (95% CI 84.6%, 93.6%), 86.2% for the N+ cohort and 96.0% for the N− cohort. Cox regression suggested that age, body mass index, ECOG PS, N+ status, stage T3 or T4, and ER+ or PR+ status were risk factors for IDR but were not statistically significant. Consistent with previous studies, this real-world study observed that patients with HER2+ BC showing pCR with nPT remain at risk for IDR, especially with node-positive disease at diagnosis. Alternatives to adjuvant trastuzumab alone, including combined trastuzumab and pertuzumab, should be considered to improve outcomes for initially N+ patients showing pCR with nPT.read more
Citations
More filters
Journal ArticleDOI
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis
Sandra M. Swain,Harrison Macharia,Javier Cortes,Chau T. Dang,Luca Gianni,Sara A. Hurvitz,Christian Jackisch,Andreas Schneeweiss,Dennis J. Slamon,Pinuccia Valagussa,Y. du Toit,Dominik Heinzmann,Adam Knott,Chunyan Song,Patricia Cortazar +14 more
TL;DR: Patients treated with dual HER2-targeted therapy in both the neoadjuvant and adjuvant settings had the highest 4-year event-free survival rates, suggesting that this treatment approach may provide the most benefit for patients with Her2-positive early breast cancer.
Journal ArticleDOI
Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival
A. van der Voort,Marte C. Liefaard,Mette S. van Ramshorst,Erik van Werkhoven,Joyce Sanders,Jelle Wesseling,Astrid N. Scholten,Marie-Jeanne T. F. D. Vrancken Peeters,Linda de Munck,Sabine Siesling,Gabe S. Sonke +10 more
TL;DR: In this article , pertuzumab was added to neoadjuvant treatment to improve pCR in early stage HER2-positive breast cancer patients, but the survival benefit was limited to node-positive patients.
Journal ArticleDOI
Markers Associated With Tumor Recurrence in Patients With Breast Cancer Achieving a Pathologic Complete Response After Neoadjuvant Chemotherapy
Li-Yun Xie,Kun Wang,Hai-Lu Chen,Yanlong Shi,Yuan-Qi Zhang,Hao-Yu Lin,Yuan-Ke Liang,Ying-Sheng Xiao,Zhiyong Wu,Zhongyu Yuan,Si Qiu +10 more
TL;DR: Clinical T stage, clinical N stage and tumor expression of ALDH3A2 were potential markers for predicting tumor recurrence in the pCR patients after NAC.
Journal ArticleDOI
Hormone receptors AR, ER, PR and growth factor receptor Her-2 expression in oral squamous cell carcinoma: Correlation with overall survival, disease-free survival and 10-year survival in a high-risk population
Yumna Adnan,Syed A. Ali,Mohammad Sohail Awan,Romana Idress,Muhammad Ozair Awan,H. Farooqui,Hammad Afzal Kayani +6 more
TL;DR: Her-2 may be a valuable marker for predicting long-term prognosis of OSCC patients and correlate it with 10-year, overall and disease-free survival, according to this study.
Journal ArticleDOI
Are We Overtreating Patients With T1a HER2+ Breast Cancer? An Analysis of the National Cancer Database.
Austin D. Williams,Odette Solis,Helene M. Sterbling,A. Murray,Olutayo A. Sogunro,Lucy M. De La Cruz +5 more
TL;DR: The use of chemotherapy in patients with HER2+ T1a cancers is increasing over time and is, as expected, more common among patients with unfavorable clinicopathologic features as discussed by the authors .
References
More filters
Journal ArticleDOI
American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff,M. Elizabeth H. Hammond,Jared N. Schwartz,Karen L. Hagerty,D. Craig Allred,Richard J. Cote,Mitchell Dowsett,Patrick L. Fitzgibbons,Wedad Hanna,Amy S. Langer,Lisa M. McShane,Soonmyung Paik,Mark D. Pegram,Edith A. Perez,Michael F. Press,Anthony Rhodes,Catharine M. Sturgeon,Sheila E. Taube,Raymond R. Tubbs,Gail H. Vance,Marc J. van de Vijver,Thomas M. Wheeler,Daniel F. Hayes +22 more
TL;DR: A testing algorithm that relies on accurate, reproducible assay performance, including newly available types of brightfield ISH, is proposed and strongly recommends validation of laboratory assay or modifications, use of standardized operating procedures, and compliance with new testing criteria to be monitored.
Journal ArticleDOI
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar,Lijun Zhang,Michael Untch,Keyur Mehta,Joseph P. Costantino,Norman Wolmark,Hervé Bonnefoi,David Cameron,Luca Gianni,Pinuccia Valagussa,Sandra M. Swain,Tatiana M. Prowell,Sibylle Loibl,D. Lawrence Wickerham,Jan Bogaerts,José Baselga,Charles M. Perou,Gideon M. Blumenthal,Jens Uwe Blohmer,Eleftherios P. Mamounas,Jonas Bergh,Vladimir Semiglazov,Robert Justice,Holger Eidtmann,Soonmyung Paik,Martine Piccart,Rajeshwari Sridhara,Peter A. Fasching,Leen Slaets,Shenghui Tang,Bernd Gerber,Charles E. Geyer,Richard Pazdur,Nina Ditsch,Priya Rastogi,Wolfgang Eiermann,Gunter von Minckwitz +36 more
TL;DR: In this paper, the authors compared the three most commonly used definitions of pathological complete response (ypT0 ypN0, ypT0/is ypNs0, and ypTsN0/IsYPN0) for their association with EFS and overall survival in clinical trials of neoadjuvant treatment of breast cancer.
Journal ArticleDOI
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Antonio C. Wolff,M. Elizabeth H. Hammond,Jared N. Schwartz,Karen L. Hagerty,D. Craig Alfred,Richard J. Cote,Mitchell Dowsett,Patrick L. Fitzgibbons,Wedad Hanna,Amy S. Langer,Lisa M. McShane,Soonmyung Paik,Mark D. Pegram,Edith A. Perez,Michael F. Press,Anthony Rhodes,Catharine M. Sturgeon,Sheila E. Taube,Raymond R. Tubbs,Gail H. Vance,Marc J. van de Vijver,Thomas M. Wheeler,Daniel F. Hayes +22 more
TL;DR: A testing algorithm that relies on accurate, reproducible assay performance, including newly available types of brightfield ISH, is proposed and strongly recommends validation of laboratory assay or modifications, use of standardized operating procedures, and compliance with new testing criteria are recommended.
Journal ArticleDOI
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
Jeffrey S. Ross,Elzbieta A. Slodkowska,W. Fraser Symmans,Lajos Pusztai,Peter M. Ravdin,Gabriel N. Hortobagyi +5 more
TL;DR: The review concludes with a consideration of HER-2 status in the prediction of response to non-HER-2 targeted treatments including hormonal therapy, anthracyclines, and taxanes.
Journal ArticleDOI
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Jose Baselga,Sandra M. Swain +1 more
TL;DR: The role of two important family members of the epidermal growth factor receptor (Erbb) family is re-evaluate, the mechanisms of action are explored and preclinical and clinical data for new therapies that target signalling through these pivotal receptors are explored.